Published in PLoS One on January 25, 2016
Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A (1998) 192.97
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A (2001) 132.88
Immunity, inflammation, and cancer. Cell (2010) 28.27
Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature (2005) 15.83
Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci U S A (2004) 10.99
Integrative molecular concept modeling of prostate cancer progression. Nat Genet (2006) 8.49
Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell (2003) 8.11
Pten dose dictates cancer progression in the prostate. PLoS Biol (2003) 7.62
Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell (2003) 6.38
Integrative clinical genomics of advanced prostate cancer. Cell (2015) 5.29
Prostate cancer and inflammation: the evidence. Histopathology (2012) 2.60
Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer Cell (2015) 2.57
Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell (2007) 2.48
Molecular classification of prostate cancer using curated expression signatures. Proc Natl Acad Sci U S A (2011) 2.46
Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity. Cancer Metastasis Rev (2010) 2.41
The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis. Nat Cell Biol (2014) 2.27
Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias. Cancer Genet Cytogenet (2006) 2.23
Tracking the origin of metastatic prostate cancer. Eur Urol (2014) 2.20
Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis. Cancer Res (2005) 2.19
Genetic background controls tumor development in PTEN-deficient mice. Cancer Res (2006) 1.63
Exome sequencing of prostate cancer supports the hypothesis of independent tumour origins. Eur Urol (2012) 1.60
The complexity of prostate cancer: genomic alterations and heterogeneity. Nat Rev Urol (2012) 1.59
Epigenetics in prostate cancer: biologic and clinical relevance. Eur Urol (2011) 1.49
alpha 2-Macroglobulin, complement, and biologic defense: antigens, growth factors, microbial proteases, and receptor ligation. Lab Invest (1994) 1.33
Loss of Nkx3.1 leads to the activation of discrete downstream target genes during prostate tumorigenesis. Oncogene (2009) 1.28
Temporally controlled ablation of PTEN in adult mouse prostate epithelium generates a model of invasive prostatic adenocarcinoma. Proc Natl Acad Sci U S A (2008) 1.26
Accumulating progenitor cells in the luminal epithelial cell layer are candidate tumor initiating cells in a Pten knockout mouse prostate cancer model. PLoS One (2009) 1.24
Genomic profiling defines subtypes of prostate cancer with the potential for therapeutic stratification. Clin Cancer Res (2013) 1.16
Genomic, pathological, and clinical heterogeneity as drivers of personalized medicine in prostate cancer. Urol Oncol (2014) 1.16
Prostate inflammation and its potential impact on prostate cancer: a current review. J Cell Biochem (2008) 1.14
Intraductal carcinoma of the prostate without invasive carcinoma on needle biopsy: emphasis on radical prostatectomy findings. J Urol (2010) 1.11
Cytoplasmic PTEN protein loss distinguishes intraductal carcinoma of the prostate from high-grade prostatic intraepithelial neoplasia. Mod Pathol (2012) 1.07
Association between tumor-associated macrophage infiltration, high grade prostate cancer, and biochemical recurrence after radical prostatectomy. Am J Cancer Res (2013) 1.04
Slow disease progression in a C57BL/6 pten-deficient mouse model of prostate cancer. Am J Pathol (2011) 1.01
Patterns of high-grade prostatic intraepithelial neoplasia associated with clinically aggressive prostate cancer. Hum Pathol (1998) 1.01
Immune Infiltration and Prostate Cancer. Front Oncol (2015) 0.98
High-resolution genome-wide copy-number analysis suggests a monoclonal origin of multifocal prostate cancer. Genes Chromosomes Cancer (2012) 0.96
Utility of PTEN and ERG immunostaining for distinguishing high-grade PIN from intraductal carcinoma of the prostate on needle biopsy. Am J Surg Pathol (2015) 0.93
Prostate cancer as a model system for genetic diversity in tumors. Adv Cancer Res (2011) 0.91
Markers of prostate region-specific epithelial identity define anatomical locations in the mouse prostate that are molecularly similar to human prostate cancers. Differentiation (2007) 0.89
The pace of prostatic intraepithelial neoplasia development is determined by the timing of Pten tumor suppressor gene excision. PLoS One (2008) 0.89
Molecular analysis of multifocal prostate cancer by comparative genomic hybridization. Prostate (2008) 0.87
The presence and clinical implication of intraductal carcinoma of prostate in metastatic castration resistant prostate cancer. Prostate (2015) 0.87
Genetic background influences murine prostate gene expression: implications for cancer phenotypes. Genome Biol (2007) 0.86
Androgen deprivation induces phenotypic plasticity and promotes resistance to molecular targeted therapy in a PTEN-deficient mouse model of prostate cancer. Carcinogenesis (2014) 0.86
Not all gleason pattern 4 prostate cancers are created equal: A study of latent prostatic carcinomas in a cystoprostatectomy and autopsy series. Prostate (2015) 0.85
Conditional deletion of the Pten gene in the mouse prostate induces prostatic intraepithelial neoplasms at early ages but a slow progression to prostate tumors. PLoS One (2013) 0.85
Immunohistochemical analysis of inflammatory cells in benign and precancerous lesions and carcinoma of the prostate. Pathobiology (2013) 0.84
Histologic changes associated with neoadjuvant chemotherapy are predictive of nodal metastases in patients with high-risk prostate cancer. Am J Clin Pathol (2010) 0.83
Changes in connexin43 expression and localization during pancreatic cancer progression. J Membr Biol (2012) 0.82
Intraductal carcinoma of the prostate: a comprehensive and updated review. Int J Urol (2014) 0.81
Trefoil factors are expressed in human and rat endocrine pancreas: differential regulation by growth hormone. Endocrinology (2006) 0.80
Gastrin-releasing peptide as a molecular target for inflammatory diseases: an update. Inflamm Allergy Drug Targets (2013) 0.80
Intraductal carcinoma of the prostate: a distinct histopathological entity with important prognostic implications. J Clin Pathol (2009) 0.79